Anti-IL-17R/IL-17RA (CD217) antibody

Cat.#: 105072

Special Price 290.3 USD

Availability: In Stock
- +

Add to cart to get an online quotation

Product Information

  • Product Name
    Anti-IL-17R/IL-17RA (CD217) antibody
  • Documents
  • Description
    Rabbit monoclonal to IL-17R/IL-17RA (CD217)
  • Tested applications
    B/N
  • Species reactivity
    Human IL-17R / IL-17RA / CD217
    Has cross-reactivity with Cynomolgus IL17RA (504722) and Mouse IL17RA (501863) in ELISA assay
  • Alternative names
    Cdw217 antibody; AW538159 antibody; CD217 antibody; CDw217 antibody; hIL-17R antibody; Il17r antibody; IL17R antibody; IL-17R antibody; Il17ra antibody; IL17RA antibody; MGC10262 antibody; VDw217 antibody; Cdw217 antibody; Il17r antibody; VDw217 antibody; AW538159 antibody; CD217 antibody; IL17R antibody; CANDF5 antibody; CDw217 antibody; IL-17RA antibody; hIL-17R antibody
  • Immunogen
  • Isotype
    Rabbit IgG
  • Preparation
    This antibody was obtained from a rabbit immunized with purified, recombinant Human IL-17R / IL-17RA / CD217 (rh IL-17R / IL-17RA / CD217; NP_055154.3; Met1-Trp320) and was produced using recombinant antibody technology.
  • Clonality
    Monoclonal
  • Formulation
    0.2 μm filtered solution in Histidine and Arginine buffer containing 120mM NaCl, 0.02% Tween 80, pH6.0
  • Storage instructions
    This antibody can be stored at 2℃-8℃ for one month without detectable loss of activity. Antibody products are stable for twelve months from date of receipt when stored at -20℃ to -80℃. Preservative-Free.Sodium azide is recommended to avoid contamination (final concentration 0.05%-0.1%). It is toxic to cells and should be disposed of properly. Avoid repeated freeze-thaw cycles.
  • Applications
    Block - This antibody can block the binding of recombinant IL17a to its recombinant receptor IL17Ra.
    Neutralization - The neutralization activity of IL17Ra neutralizing antibody is measured by its ability to neutralize IL6 secretion induced by human IL17a in the HFF human foreskin fibroblast.The Neutralization Titer (IC50) is typically 0.30-0.70 µg/mL in the presence of 50 ng/mL Recombinant Human IL17a.
  • Validations

    IL-17R / IL-17RA / CD217 Neutralizing Antibody

    IL-17R / IL-17RA / CD217 Neutralizing Antibody

    IL6 secretion in the HFF human foreskin fibroblast elicited by 50 ng/mL of Recombinant Human IL17a is neutralized by increasing concentrations of Human IL17Ra Monoclonal Antibody (Catalog 10895-R004), as measured by IL6 Quantitative ELISA Kit (KIT10395). The IC50 is typically 0.30-0.70 μg/mL. IL6 secretion in the HFF human foreskin fibroblast elicited by 50 ng/mL of Recombinant Human IL17a is neutralized by increasing concentrations of Human IL17Ra Monoclonal Antibody (Catalog 10895-R004), as measured by IL6 Quantitative ELISA Kit (KIT10395). The IC50 is typically 0.30-0.70 μg/mL.

  • Background
    Interleukin-17 receptor (IL-17R), also known as Interleukin-17 receptor A (IL-17RA) and CD217 antigen (CD217), is a cytokine receptor which binds interleukin 17. IL-17R/IL-17RA (CD217) is a proinflammatory cytokine secreted by activated T-lymphocytes. It is a potent inducer of the maturation of CD34-positive hematopoietic precursors into neutrophils. IL-17R/IL-17RA (CD217) is a ubiquitous type I membrane glycoprotein that binds with low affinity to interleukin 17A. Interleukin 17A and its receptor IL-17RA play a pathogenic role in many inflammatory and autoimmune diseases such as rheumatoid arthritis. Like other cytokine receptors, this receptor likely has a multimeric structure. Defects in IL-17R/IL-17RA (CD217) are the cause of familial candidiasis type 5 (CANDF5). CANDF5 is a rare disorder with altered immune responses and impaired clearance of fungal infections, selective against Candida. It is characterized by persistent and/or recurrent infections of the skin, nails and mucous membranes caused by organisms of the genus Candida, mainly Candida albicans.
  • References
    • Gaffen SL. (2009) Structure and signalling in the IL-17 receptor family. Nat Rev Immunol. 9 (8): 556-67.
    • Johansen C, et al.. (2009) Characterization of the interleukin-17 isoforms and receptors in lesional psoriatic skin. Br J Dermatol. 160 (2): 319-24.
    • Yao Z, et al.. (1997) Molecular characterization of the human interleukin (IL)-17 receptor. Cytokine 9 (11): 794-800.

Please note: All products are "FOR RESEARCH USE ONLY AND ARE NOT INTENDED FOR DIAGNOSTIC OR THERAPEUTIC USE"